Valo: adding tumor antigens to oncolytic viruses
Valo’s platforms use physical interactions for viral display of tumor antigens without genetic engineering
With platforms that can rapidly display tumor-specific antigens on oncolytic viruses without genetic engineering, Valo is positioning itself as an attractive collaborator for immuno-oncology companies.
Oncolytic viruses kill cancer cells by lysing the cells, and are engineered to amplify antitumor immune responses through expression of immuno-stimulatory genes.
By adding targeted antigens to viral surfaces, Valo Therapeutics Ltd. thinks the viruses can get a more specific antitumor response.
CEO Michael Stein said the